

*Annual Review of Microbiology***Antibiotic-Induced Genetic Variation: How It Arises and How It Can Be Prevented****Jesús Blázquez,<sup>1,2,3,\*</sup> Jerónimo Rodríguez-Beltrán,<sup>4,\*</sup> and Ivan Matic<sup>5</sup>**

<sup>1</sup>Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CNB-CSIC), 28049 Madrid, Spain; email: blazquez@cnb.csic.es

<sup>2</sup>Unidad de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospital Universitario Virgen del Rocío, 41013 Seville, Spain

<sup>3</sup>Red Española de Investigación en Patología Infecciosa, Instituto de Salud Carlos III, 28029 Madrid, Spain

<sup>4</sup>Instituto Ramón y Cajal de Investigación Sanitaria, 28034 Madrid, Spain; email: jeronimo.rodriguez.beltran@gmail.com

<sup>5</sup>Faculté de Médecine Paris Descartes, INSERM 1001, CNRS, Université Paris-Descartes-Sorbonne Paris Cité, 75014 Paris, France; email: ivan.matic@inserm.fr

**ANNUAL  
REVIEWS CONNECT**

[www.annualreviews.org](http://www.annualreviews.org)

- Download figures
- Navigate cited references
- Keyword search
- Explore related articles
- Share via email or social media

Annu. Rev. Microbiol. 2018. 72:209–30

The *Annual Review of Microbiology* is online at [micro.annualreviews.org](http://micro.annualreviews.org)

<https://doi.org/10.1146/annurev-micro-090817-062139>

Copyright © 2018 by Annual Reviews.  
All rights reserved

\*These authors contributed equally to this work

**Keywords**

antibiotic resistance, genetic instability, mutation rates, mutagenesis, SOS, ROS, evolvability

**Abstract**

By targeting essential cellular processes, antibiotics provoke metabolic perturbations and induce stress responses and genetic variation in bacteria. Here we review current knowledge of the mechanisms by which these molecules generate genetic instability. They include production of reactive oxygen species, as well as induction of the stress response regulons, which lead to enhancement of mutation and recombination rates and modulation of horizontal gene transfer. All these phenomena influence the evolution and spread of antibiotic resistance. The use of strategies to stop or decrease the generation of resistant variants is also discussed.

## Contents

INTRODUCTION .....	210
ANTIBIOTIC-INDUCED MUTAGENESIS .....	211
Oxidative Metabolism .....	212
The SOS Response .....	214
The RpoS-Regulated General Stress Response .....	215
ANTIBIOTIC-INDUCED RECOMBINATION .....	215
ANTIBIOTICS AS SELECTORS OF HYPERMUTABLE BACTERIA .....	215
IS ANTIBIOTIC-INDUCED GENETIC VARIATION BIOLOGICALLY AND CLINICALLY RELEVANT? .....	216
TARGETING EVOLUTION OF ANTIBIOTIC RESISTANCE .....	217
SOS Inhibitors .....	217
Horizontal Gene Transfer Inhibitors .....	222
CONCLUDING REMARKS .....	223

In life, unlike chess, the game continues after checkmate.

—Isaac Asimov (1920–1992)

## INTRODUCTION

The beginning of mass production of antibiotics over half a century ago was a major breakthrough in medical treatment of infectious diseases and was the advent of modern medical practices, including complicated surgical interventions and cancer treatments (see the sidebar titled Note). Without effective antibiotics, modern medicine is simply unfeasible. For several generations, we have lived in a comfortable era in which most bacterial infections have been resolved successfully with antimicrobial drugs. As a result of the extensive use and misuse of antibiotics in human and veterinary medicine and in agriculture (1, 25, 104, 158), the tremendous emergence and spread of antibiotic resistance among bacterial pathogens in recent decades has threatened this idyllic world. The problem has been exacerbated by waning pharmaceutical investment in research for new antimicrobial drugs. There is thus an urgent need to take measures to avoid returning to the preantibiotic era (6). The development of new antibiotics, the implementation of methods to increase treatment efficiency, and a better understanding of the impact of antibiotics on bacteria and their responses are among these necessary measures (73).

## NOTE

According to Waksman, an antibiotic is a chemical substance produced by microorganisms with the capacity to inhibit growth of and destroy bacteria and other microorganisms (154). Nonetheless, some synthetic substances such as quinolones, sulphonamides, and oxazolidinones (defined as antimicrobials elsewhere) have the same activity profiles but are not encompassed by this definition. For the sake of simplicity, in this review we will use both terms without distinction.

The concurrence of genetic variation and natural selection is the most fundamental force in biology. Seminal studies demonstrated that exposure of bacteria to effective concentrations of antibacterial agents, including bacteriophages, selects for preexisting resistant variants that eventually become fixed in the population (115). The evolution of antibiotic resistance is obviously based on genetic variation and selection of the resistant variants. It has nonetheless become clear that antibiotics do more than simply select for resistant variants. At subinhibitory concentrations, they induce bacterial responses, including mechanisms that accelerate the adaptation rate (22, 50, 138). Here it is important to highlight that the inhibitory effect of an antibiotic is not only related to the intrinsic susceptibility of a strain, antibiotic concentration, or a specific environment; time of exposure is also relevant to antibiotic activity. Exposure to high antibiotic concentrations for a very short period can have the same effect as challenges with subinhibitory concentrations for longer times. Here we therefore consider subinhibitory concentrations to be those that do not stop growth or kill the challenged bacteria, independently of drug concentration.

From a clinical perspective, it has been assumed that only antibiotic resistance levels above a defined threshold (related to antibiotic concentration at the site of infection as well as strain susceptibility) are relevant for evolution of resistance. For this reason, the impact of subinhibitory antibiotic concentrations on bacterial evolution to resistance has long been neglected, although it was recognized as an important step on the selective paths to strong resistance (15). Recent information indicates that very low antibiotic concentrations can select not only for low-level resistance (12) but also for high-level resistance (65).

Bacteria frequently encounter low concentrations of antibiotics in their environment. When antibiotics are used therapeutically or for growth promotion, for example, bacterial populations face wide gradients of antibiotic concentrations in compartmentalized animal or human bodies. These gradients are due to pharmacokinetic factors such as different diffusion rates into various cell or tissue types, metabolism, local binding or inactivation, or variation in the elimination rate from different body compartments (15). The direct effect of normal or pathogenic microbiota, particularly if they possess antibiotic-inactivating enzymes, can also contribute to gradient formation. Because antibiotics are poorly absorbed by the gut, 30–90% of ingested antibiotics are excreted unchanged via urine and feces from human and animal bodies (see for example Reference 128). Some antibiotics have high persistence in the environment; for example, azithromycin and amoxicillin are commonly found in soil and water (82, 84). Some molecules such as sulfamethoxazole, erythromycin, and the antifolate trimethoprim are even more concentrated after wastewater treatment due to deconjugation of their metabolites, which restores the parent molecules (130). Fluoroquinolone concentration can be particularly high in dry mass of farmyard manure and of sewage sludge (63). Finally, antibiotics are also excreted by antibiotic-producing microorganisms in all environments. The omnipresent low doses of antibiotics in the environment, together with their major impact on bacterial homeostasis and genetic stability, set the perfect scenario for antibiotics to have an important role in the evolution of antibiotic resistance (5, 103).

In this review, we discuss current knowledge of how antibiotics cause bacterial genetic instability and thus influence the evolution and spread of resistance determinants in different ways, including enhancement of mutation and recombination, horizontal gene transfer (HGT), and promotion of adaptive responses. These last two processes will not be treated here, however, as they have been covered extensively in several fine reviews on antibiotic side effects (5, 41, 59, 67, 75, 98). Finally, we discuss the possibility of using strategies to halt or reduce the generation of resistant variants.

## ANTIBIOTIC-INDUCED MUTAGENESIS

Mutations can contribute to antibiotic resistance in a number of ways. They can confer resistance by modifying genes coding for the antibiotic targets, attenuate fitness reduction associated

---

### Subinhibitory concentrations:

concentrations that do not stop growth or kill the challenged bacteria; experimental conditions must be defined when a value is provided

---


with acquired antibiotic resistance, or modify activity and the resistance spectrum of horizontally transferred resistance determinants. Indeed, even a slight increase in mutation rates contributes significantly to the evolution of antibiotic resistance (40, 42, 43, 121). Spontaneous mutation rates are maintained at low levels by a multitude of molecular mechanisms that include metabolic control over concentrations of endogenous and exogenous mutagens, DNA repair systems, dNTP pool balance, base selection and proofreading activity of replicative DNA polymerases, and several postreplication systems for repairing mismatches (106). When normal cell function is disturbed by environmental factors that reduce fitness and/or increase mortality, mutation rates also commonly increase. Antibiotics are among the environmental factors known to increase mutation rates (5, 22, 88); they induce mutagenesis during exposure of bacterial populations to lethal concentrations of antibiotics, but also during exposure to subinhibitory concentrations in many species, including *Acinetobacter baumannii*, *Enterobacter cloacae*, *Escherichia coli*, *Mycobacterium fortuitum*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella enterica* Typhimurium, *Staphylococcus aureus*, *Streptococcus pneumoniae*, and *Vibrio cholerae* (7, 11, 24, 30, 45, 54, 56, 57, 66, 68, 81, 86, 88, 92, 96, 126, 134, 137, 147–149, 152).

Low doses of antibiotics, both bactericidal and bacteriostatic, with very different cellular targets increase mutagenesis in bacteria (11, 149). It is not surprising that antibiotics like trimethoprim and the fluoroquinolone ciprofloxacin, which directly affect DNA replication and genome integrity, can increase mutation rates (57, 147, 153). What was not anticipated, however, is that many antibiotics that do not affect DNA directly, such as the  $\beta$ -lactam ampicillin or the aminoglycoside streptomycin (which interfere respectively with synthesis of the peptidoglycan layer and with protein synthesis), also increase mutation rates (66, 134). These observations suggest that antibiotics can affect mutation rates by a wide variety of mechanisms. Current knowledge of the mechanisms of antibiotic-induced mutagenesis indicates that they can be classified in three largely overlapping groups: oxidative metabolism and the SOS and the RpoS-regulated general stress responses (**Figure 1**).

## Oxidative Metabolism

Oxidative metabolism is a process in which oxygen is used to generate energy from nutrients. In bacteria growing in aerobic conditions, most energy is produced by respiration using molecular oxygen as the final electron acceptor, although unwanted by-products of respiration are reactive oxygen species (ROS). The major source of endogenous ROS production is accidental autoxidation of respiratory enzymes and electron leakage (78). ROS are formed continuously but are also eliminated continuously by superoxide dismutase transformation of superoxide to hydrogen peroxide, and by peroxidases and catalases that degrade hydrogen peroxide. Hydrogen peroxide is a liability for the cell, as its reduction by redox-active metals such as iron produces highly reactive hydroxyl radicals that cannot be eliminated by an enzymatic reaction. These radicals are very toxic since they react with all cell macromolecules: nucleic acids, amino acids, carbohydrates, and lipids. Bacteria have defense mechanisms just sufficient to protect themselves against endogenous ROS. For instance, *E. coli* superoxide dismutase mutants and *fur* mutants, which have elevated intracellular iron content, show high spontaneous mutation rates (78). A stress-induced increase in ROS production thus has deleterious consequences, including increased mutation rates. Some studies have reported that treatment with ampicillin, kanamycin, norfloxacin, ciprofloxacin, or trimethoprim increases ROS production and mutation rates in *E. coli* (57, 62, 86, 149).

This increase in mutagenesis can be prevented by the ROS scavenger thiourea (113), by anaerobic conditions, or by inactivating the *tonB* gene, which reduces extracellular iron importation and thus lowers hydroxyl radical production (57). Levels of 8-oxo-deoxyguanosine (8-oxo-dG), the most mutagenic ROS-oxidized molecule, increase in the DNA of ampicillin-



**Figure 1**

How antibiotics modulate mutation rates in bacterial cells. Different antibiotics have distinct cellular targets: quinolones and antifolates block DNA replication,  $\beta$ -lactams affect peptidoglycan synthesis, and aminoglycosides perturb protein synthesis. Treatment with DNA replication inhibitors increases mutagenesis, as they induce SOS-controlled, error-prone translesion synthesis (TLS) DNA polymerases (blue). Other antibiotics, which do not target DNA, increase mutation rates because they cause metabolic perturbations (purple). Antibiotic-treated cells increase energy production, as well as translation and macromolecular repair and protection capacity, to control antibiotic-induced damage and restore growth. Increased energy requirements need cell respiratory activity, which results in increased ROS production (red). ROS damage DNA and hence contribute to increased mutagenesis. Elevated energy production also causes accelerated nutrient depletion that in turn triggers RpoS regulon (green) induction. Induction of this regulon results in increased mutagenesis, since it inhibits activity of the mismatch repair system (magenta), a major guardian of genetic stability, and because it stimulates activity of the TLS DNA polymerases. Abbreviation: ROS, reactive oxygen species.

kanamycin- or norfloxacin-treated cells compared to untreated *E. coli* cells (18); ampicillin-induced mutation rates are suppressed by catalase overexpression in *E. coli* (81). Mutations induced by subinhibitory concentrations of streptomycin, which also increase translation errors, are predominantly A:T to T:A and G:C to T:A transversions, both hallmarks of oxidative DNA damage (106). ROS are also good SOS inducers, as they damage DNA directly (87). In addition, protein mistranslation caused by oxidative damage leads to the collapse of replication forks, which induces the SOS response (2). ROS therefore contribute cumulatively to the mutagenic effect of antibiotics (see below). In addition, ROS appear to be major contributors to the ciprofloxacin-induced SOS response and mutagenesis in *E. coli* (A. Rodriguez-Rosado, personal communication).

Respiratory activity increases in antibiotic-treated (stressed) cells, giving rise to higher ROS levels (47, 95). Stressed cells probably increase respiratory activity because they need more energy

to repair macromolecular damage and restore growth. For example, ATP levels increase in ultraviolet- and nalidixic acid-treated *E. coli* cells; levels drop when DNA lesions are repaired in wild-type cells but remain high in *recA* mutants, which cannot repair DNA lesions (16, 38). In addition, antibiotic-treated cells have increased translational capacity, which is also very energy-consuming (103). ROS cannot be produced in the absence of oxygen. In anaerobic conditions, however, nitrate respiration contributes to ampicillin, gentamicin, norfloxacin, and trimethoprim cytotoxicity in *E. coli* (47, 57). It could thus be hypothesized that antibiotics increase mutagenesis through anaerobic respiration-mediated production of reactive species. Nonetheless, some studies detected no ROS signatures in ciprofloxacin- or norfloxacin-mediated mutations in *E. coli* (96, 147).

## The SOS Response

Antibiotics belonging to different classes induce the SOS response in distinct gram-positive and -negative bacterial species (10, 11, 58, 93, 101, 105, 145, 162, 163). The SOS response is a coordinated cellular response to DNA damage and replication blockage. During normal growth, the LexA protein represses genes of the SOS regulon. The SOS response inducer is single-stranded DNA (ssDNA) when it accumulates at above-physiological levels. Contact with ssDNA activates RecA protein coprotease activity, which promotes the proteolytic autocleavage LexA, thus activating the SOS response. The relative strength of LexA binding to its promoters determines the sequential order of gene induction during the SOS response. Once DNA damage is repaired, DNA replication is restarted, ssDNA disappears, and the SOS regulon is re-repressed. In *E. coli*, the SOS regulon is composed of at least 40 genes, many of which code for DNA repair functions such as nucleotide excision repair, translesion synthesis (TLS), and homologous recombination (144). SOS regulons are found in many other bacterial species, with conserved LexA/RecA regulatory core and variable gene content (48). Antibiotic-induced mutagenesis can therefore be considered SOS dependent, as it requires functional RecA and LexA regulatory proteins. Based on this criterion, a variety of antibiotics from different families induce SOS-dependent mutagenesis in *E. coli*, *P. aeruginosa*, *S. aureus*, and *V. cholerae* (11, 71, 111, 112, 149).

Antibiotics induce SOS by a variety of molecular mechanisms; for example, dTTP depletion by trimethoprim blocks DNA replication (57, 139), SOS induction by  $\beta$ -lactams involves the DpiBA two-component system in *E. coli* (105), and SOS induction by tobramycin is triggered by RNA polymerase stalling in *V. cholerae* (9). Antibiotic-induced SOS-dependent mutagenesis relies on a single group of terminal effectors, the Y family TLS DNA polymerases. Inactivation of TLS polymerase-encoding genes abolishes antibiotic-induced mutagenesis in *A. baumannii*, *E. coli*, *P. aeruginosa*, and *V. cholerae* (7, 30, 66, 124).

The common characteristic of TLS polymerases is the ability to by-pass DNA lesions that block replicative DNA polymerases (151). TLS polymerases are inherently error prone, as they by-pass noncoding lesions and have no proofreading activity. Overexpression of genes coding for TLS polymerases that results from induction of the SOS regulon can be sufficient to increase mutagenesis. The propensity of the TLS polymerases to incorporate mutagenic oxidized nucleotides into DNA might also be responsible for antibiotic-induced mutagenesis associated with oxidative stress (51, 160).

*E. coli* has two Y family TLS polymerases, pol IV and pol V, encoded by the *dinB* and *umuCD* genes, respectively (116). Chromosomes of most bacterial species have homologs of these two DNA polymerases, which are also carried by naturally occurring plasmids and integrating conjugative elements (79, 151). Because TLS polymerases encoded by plasmid-borne genes are very error prone, Ames and colleagues (92) introduced R-plasmid pKM101, which encodes the pol V orthologs *mucAB* in *S. Typhimurium* tester strains developed to identify potential mutagens and



carcinogens. MucAB greatly increases fluoroquinolone-induced mutagenesis in *S. Typhimurium* (163).

Other results show antibiotic-mediated mutagenesis independent of TLS polymerases. For instance, some ciprofloxacin-induced genetic changes in *E. coli*, such as deletions, do not require any SOS-induced polymerase (147). A study by Pomerantz et al. (129) suggests the participation of DNA pol I in this TLS-independent mutagenesis. Pol I normally exhibits high-fidelity DNA synthesis but is very error prone at the RecA-mediated D-loops produced by double-strand break repair (129). The double-strand break produced by some antibiotics such as ciprofloxacin can generate these RecA-mediated D-loops and cause subsequent TLS-independent mutagenesis.

---

**Sigma ( $\sigma$ ) factors:** proteins that enable specific binding of RNA polymerase to gene promoters to initiate transcription; they provide effective mechanisms for regulating large numbers of genes

---

## The RpoS-Regulated General Stress Response

The general stress response regulon, which is controlled by the alternative RNA polymerase sigma factor RpoS ( $\sigma^S$ ), is conserved in many bacterial species (28). This regulon comprises hundreds of functionally unrelated genes and can be induced by a wide range of stress conditions, including nutrient starvation, heat shock, low pH, and oxidative or osmotic shock, as well as bactericidal and bacteriostatic antibiotics (17, 39, 66, 103). Subinhibitory concentrations of certain antibiotics induce the RpoS regulon, because increased energy production and translation capacity in treated cells accelerates nutrient depletion and triggers the stringent response in *E. coli* (103); the RpoS regulon can also be induced by treatment-triggered ROS production (39). Induction of the RpoS regulon increases  $\beta$ -lactam-induced mutagenesis in *E. coli*, *P. aeruginosa*, and *V. cholerae* (66). In these species, mutations are generated by the *dinB*-encoded TLS polymerase, which is regulated by RpoS in addition to LexA (53). These mutations are fixed, however, due to the reduced mismatch repair (MMR) activity mediated by SdsR, the RpoS-controlled small RNA (66).

## ANTIBIOTIC-INDUCED RECOMBINATION

Recombination is thought to be under strong selective pressure in bacterial populations, as indicated by the differences in recombination rates between bacterial species (44), as well as between commensal and pathogenic strains of the same species (135). Recombination thus seems to play a crucial role in bacterial evolution. Antibiotics can also affect recombination. Subinhibitory ciprofloxacin concentrations stimulate both intra- and interchromosomal recombination between identical and divergent sequences in *E. coli*, independently of SOS response induction (97). This antibiotic also stimulates recombination in MMR-deficient mutator strains; fortunately, stimulation of homologous recombination appears to be specific to fluoroquinolones, as it was not observed for ten other antibiotics of different chemical classes with distinct molecular targets (97).

A particular case is site-specific recombination, a process by which specialized recombinases recognize and target specific DNA sequences. For instance, the integron integrases are induced by antibiotics in a SOS-dependent manner, in both laboratory (64) and clinical settings (72). The site-specific recombinase gene *ccrCI* is similarly induced by several clinically relevant antibiotics in *S. aureus*, leading to transfer of the SCC $_{mec}$  chromosomal cassette, which confers methicillin resistance (94). Similar examples of SOS-controlled, site-specific recombinases and other mobile genetic elements are abundant and have been reviewed recently (49).

## ANTIBIOTICS AS SELECTORS OF HYPERMUTABLE BACTERIA

Bacterial cells with increased frequency of mutations (hypermutators or mutators) have an increased probability of acquiring favorable mutations, including those that confer antibiotic

resistance. In certain conditions, hypermutable alleles can thus accelerate the evolutionary rate and confer an indirect selective advantage on the strains that carry them (34, 55). Unfortunately, the opposite is also true, as antibiotic pressure selects for hypermutator clones (102). Selection for a single mutation increases the proportion of mutators in the population from the original 0.001% (the normal frequency in an *E. coli* population) to as much as 0.5%. Successive selection steps can further increase the proportion of mutator strains up to 100% (102). Mutator alleles remain linked to the beneficial mutations they produce, a process known as second-order selection or genetic hitchhiking (102, 142). Because bacterial populations can face successive or alternative antibiotic challenges, particularly in chronic infections, mutators become more frequent in the challenged population. A given antibiotic can therefore select not only for resistance to itself but also, indirectly, for increased capacity to acquire resistance to unrelated antibiotics. This relationship was illustrated by the demonstration that *P. aeruginosa* hypermutable strains are selected in patients with cystic fibrosis or chronic obstructive pulmonary disease; these strains become highly resistant to a large number of antibiotics (100, 120).

Heritable hypermutation in bacteria is mainly due to alterations in genes of the MMR system (*mutS*, *mutL*, *wvrD*), which corrects mismatches produced during DNA replication (119, 120, 131). Deficiency in other antimutator genes, such as *mutT* (which removes 8-oxo-G and 8-oxo-dG) and *mutY* and *mutM* (which eliminate mistakes produced by 8-oxo-dG incorporation into DNA), is also found among *P. aeruginosa* mutator strains in cystic fibrosis patients (29). A noncanonical MMR system was recently identified in the major human pathogen *Mycobacterium tuberculosis*, a species that lacks the classical MutS/MutL protein-based MMR (27). Polymorphisms that affect the activity of NucS, the key protein in this noncanonical MMR, were found in clinical strains; these polymorphisms produce hypermutable phenotypes, which suggests that hypermutators can also be selected in *M. tuberculosis*.

It is argued that the probability of fixation of a resistance mutation is not greatly limited by the mutation supply rate, because bacterial population size in an infected individual exceeds  $10^{10}$ , which implies that preexisting resistant mutants are present in the infecting population when treatment begins (76). In some situations, a high mutation rate could nonetheless be essential for developing resistance. In *E. coli*, clinical resistance to some antibiotics such as fluoroquinolones requires more than one mutation (117), which dramatically reduces the effective population able to acquire resistance by mutation. Most resistance mutations have a high fitness cost, and additional mutations that compensate this cost must be acquired to allow the infection to thrive. In addition, treatments very often consist of a combination of two or more antibiotics. For example, the frequency of mutants resistant to the combination of ceftazidime plus fosfomycin in *P. aeruginosa* PAO1 is far below  $10^{-10}$ , whereas the frequency is considerably higher ( $10^{-8}$ ) in a hypermutable *P. aeruginosa* PAO1 *mutS* derivative (136). In all these cases, higher mutation supply rates can make the difference between bacterial survival and death.

Inactivation of the MMR system also produces an increase in recombination frequency between two divergent DNA sequences from the same or different bacterial species (132). The probability of acquiring new functions by both mutation and recombination is thus greatly increased in MMR-deficient strains.

## IS ANTIBIOTIC-INDUCED GENETIC VARIATION BIOLOGICALLY AND CLINICALLY RELEVANT?

The increased genetic variability provoked by certain antibiotics would potentially accelerate the rate at which resistance is developed. Most experiments have been carried out in *in vitro* systems, and the biological and clinical relevance of such mechanisms in promoting



evolvability (that is, the ability of a population to generate adaptive variation) is still debated. It is proposed that the genetic novelty produced by subinhibitory concentrations of antibiotics might be insufficient to increase evolvability if population size were severely reduced (33). This is because evolvability depends crucially both on the rate at which genetic diversity is produced and on population size. Using this rationale, Frenoy & Bonhoeffer (52) measured evolvability as the absolute number of rifampicin-resistant mutants in final populations of antibiotic-treated cultures. Their results suggest that despite increasing mutation rates, bactericidal antibiotics such as norfloxacin might in fact reduce evolvability by greatly reducing effective population size (52). Experimental evolution using a subinhibitory ciprofloxacin concentration showed that the SOS response contributes to bacterial fitness without increasing evolvability in *P. aeruginosa* (150). These studies challenge the view of antibiotic-induced mutagenesis as a driver of bacterial evolvability, although the discrepancies observed could be due to dissimilar experimental designs. In contrast, in vivo experimental evidence suggests that antibiotic-induced mutagenesis is crucial for development of resistance. In a paradigmatic example, Boshoff and colleagues (23) demonstrated that deletion of the SOS-controlled *dnaE2* polymerase in *M. tuberculosis* drastically reduces the appearance of resistant mutants following ciprofloxacin therapy in mice. Cirz et al. (30) showed that preventing LexA cleavage renders *E. coli* unable to evolve resistance either to ciprofloxacin or to rifampicin in a mouse thigh infection model. In accordance with these observations, inhibition of the SOS response in a neutropenic mouse model was recently shown to completely abolish emergence of resistant *E. coli* mutants after ciprofloxacin treatment (3).

Despite this accumulating evidence, it is still difficult to distinguish whether the effects of SOS induction in promoting antibiotic resistance stem from increased survival or increased mutation rates. Additional in vivo studies with appropriate controls are needed to solve this question, especially considering that modulation of bacterial evolvability has been proposed as a feasible therapeutic target (31, 37).

## TARGETING EVOLUTION OF ANTIBIOTIC RESISTANCE

It is becoming clear that targeting the mechanisms that underlie the evolution of resistance is a promising strategy for lengthening the shelf life of our antibiotic arsenal (13, 31, 37, 146). The objective of these strategies is not to kill bacteria but to inhibit the development and spread of resistance. As resistance to antibiotics depends on generation of genetic variability and the effect of selective pressures, several strategies have been proposed to limit selection of resistant bacteria, such as rational design of treatments to exploit collateral sensitivity networks (77, 85, 122). Here we focus on strategies that target the generation of genetic variability.


### SOS Inhibitors

The SOS response is arguably one of the most appealing targets with which to combat the evolution of resistance, at least for two reasons. First, the SOS response is highly conserved in most bacterial phylogenetic groups (48), potentially enabling the use of broad-spectrum drugs. Second, inhibition of the SOS response not only reduces antibiotic-induced mutation, recombination, and HGT rates but also renders bacteria more sensitive to certain antibiotics; in some cases, this leads to complete reversion of bacterial resistance (111, 133). SOS inhibition might also lead to a reduction in pathogenic processes such as persistence, tolerance, infection, and expression of toxins or virulence factors (21, 46, 60, 74). It is therefore not surprising that a multitude of studies have explored SOS inhibition as a therapeutic adjuvant to limit development of antibiotic resistance (**Figure 2**; a comprehensive list is shown in **Table 1**).

---

**Evolvability:** the ability of a particular organism to undergo evolutionary variation

---



**Figure 2**

How to suppress SOS-mediated, antibiotic-induced genetic variation. Certain antibiotics cause DNA damage (*red lightning bolts*), either directly or accompanied by ROS induction. DNA damage in turn gives rise to ssDNA, triggering the ATP-dependent filamentation of RecA (*pink circles*). The active RecA-ssDNA filament catalyzes autoproteolysis of LexA (*blue hexagons*), inducing expression of the SOS genes, including *recA* and *lexA*. Several compounds that inhibit SOS induction at different steps are color coded according to class (see key in figure). For detailed information about the compounds with SOS inhibition activity, see the main text and **Table 1**. Abbreviations: PcT, phthalocyanine tetrasulfonates; ssDNA, single-stranded DNA.

Some of these approaches have exploited the natural ability of specific bacterial proteins to inhibit the SOS response. For instance, Lu and Collins (99) inserted a gene encoding an uncleavable variant of the LexA protein (*lexA3*) into the bacteriophage M13 genome. Infection of *E. coli* cells with the phage inhibited SOS induction, and the engineered phage potentiated norfloxacin activity in a murine infection model. In a very interesting approach, Yakimov et al. reproduced the RecX mechanism of action (that is, inhibition of RecA filamentation) by designing and synthesizing a small  $\alpha$ -helical peptide able not only to inhibit RecA activities in vitro but also to suppress the bacterial SOS response in *E. coli* (159). This opens up new approaches to exploiting the natural activity of some bacterial proteins and peptides, such as RdgC or PsiB, to inhibit RecA-mediated induction of the SOS response (35). Moreover, peptides could be designed to block the activity of specific SOS components such as the UmuD<sub>2</sub>C polymerase (pol V), owing to its precise posttranslational regulation (61).

**Table 1** Inhibitors of the SOS response

SOS inhibitor	Bacterial species <sup>a</sup>	Times decrease in mutagenesis (inducer) <sup>b</sup>	Other phenotypes	Proposed mechanism of action	Ref.
<b>Antimicrobials</b>					
Novobiocin	<i>Staphylococcus aureus</i>	<3 (CIP)	<ul style="list-style-type: none"> <li>■ Inhibition of <i>recA</i> and <i>umuCD</i> expression</li> <li>■ Inhibition of formation of hemolytic variants and phage transduction</li> </ul>	Alteration of supercoiling by GyrB blockage reduces <i>recA</i> expression	140, 141
	<i>Acinetobacter baumannii</i>	>100 (UV) >4 (CIP) >2 (TET)	Inhibition of <i>umuC</i> , <i>umuD</i> , <i>umuCab</i> expression after DNA damage	Reduction in the generation of ssDNA regions and in the number of DNA strand breaks made during the excision repair process	80
	<i>Pseudomonas aeruginosa</i>	~2 (CIP)	Twofold reduction in <i>recA</i> expression	ND	152
Amikacin	In vitro	ND	Inhibition of ATPase and DNA-strand-exchange activities of RecA	Direct interaction with RecA protein	157
Suramin	<i>Mycobacterium tuberculosis</i>	ND	<ul style="list-style-type: none"> <li>■ Inhibition of ciprofloxacin-induced <i>recA</i> gene expression and the SOS response</li> <li>■ Increase in the bactericidal action of ciprofloxacin</li> </ul>	Direct interaction with RecA protein	114
<b>Phage</b>					
Engineered M13-carrying <i>lexA3</i>	<i>Escherichia coli</i>	ND	Enhanced antibiotic sensitivity (murine model)	Genetic repression of the SOS response	99
<b>Peptides</b>					
4E1 peptide based on RecX	<i>Escherichia coli</i>	ND	<ul style="list-style-type: none"> <li>■ Inhibition of <i>recA</i> expression</li> <li>■ Increased sensitivity to UV</li> </ul>	Direct interaction with RecA protein	159
29-Mer peptide based on the RecA N-terminal domain	In vitro	ND	Inhibition of RecA filament assembly	Direct interaction with RecA protein	32
<b>Unclassified</b>					
Compound A1	<i>Escherichia coli</i>	ND	Inhibition of the RecA-catalyzed strand-exchange reaction	ND	156
Compounds C1 and D1	<i>Escherichia coli</i> and <i>Pseudomonas aeruginosa</i> and in vitro	ND	Inhibition of LexA autoproteolysis	ND	110

(Continued)

Table 1 (Continued)

SOS inhibitor	Bacterial species <sup>a</sup>	Times decrease in mutagenesis (inducer) <sup>b</sup>	Other phenotypes	Proposed mechanism of action	Ref.
<b>Nucleotide analogs</b>					
N6-(1-naphthyl)-ADP	In vitro	ND	Competitive inhibition of RecA ATPase activity	Direct interaction with RecA protein	89
Various NTPs	In vitro	ND	Inhibition of ATPase activity of RecA Facilitation of RecA-DNA dissociation	Interaction with DNA-RecA nucleoprotein filament or binding to inactive RecA	155
<b>Metals</b>					
Zn (II)	In vitro	ND	Inhibition of RecA ATPase activity	Metal-dependent aggregation of RecA	90
Cu (II), Hg (II)	<i>Escherichia coli</i> In vitro	5-32 (CIP)	■ Inhibition of LexA cleavage ■ Inhibition of <i>Shiga</i> toxin production Inhibition of RecA ATPase activity	Perturbation of the RecA conformation such that its ability to bind ATP is reduced Metal-dependent aggregation of RecA	24, 36 90
<b>Plant and fungus derivatives</b>					
Epiphorellic acid	In vitro	ND	Noncompetitive inhibition of RecA ATPase activity	Direct interaction with RecA protein	20
Curcumin	<i>S. Typhimurium</i> and <i>Escherichia coli</i> <i>Escherichia coli</i>	2 (UV) ND	■ Inhibition of UV-induced <i>umuCD</i> gene expression ■ Inhibition of phage reactivation Suppression of the SOS response induced by levofloxacin	ND ND	19 19
Genistein (flavonoid)	<i>S. Typhimurium</i> and <i>Escherichia coli</i>	6 (ENU)	Inhibition of <i>umuCD</i> gene expression	Reduction of the interaction of RecA protein with ssDNA	107, 161
Daidzein (flavonoid)	<i>S. Typhimurium</i> and <i>Escherichia coli</i>	ND	Inhibition of <i>umuCD</i> gene expression	ND	107
Baicalein (flavonoid)	<i>Staphylococcus aureus</i>	4 (CIP)	Inhibition of intracellular ROS and ATP levels	Combined effect of ROS inhibition and inhibition of ATP synthase	123
Tectorigenin (flavonoid)	<i>S. Typhimurium</i>	1.7 (AF-2)	Inhibition of <i>umuCD</i> gene expression	ND	109
Acacetin, apigenin, luteolin, and quercetin (flavonoids)	<i>S. Typhimurium</i>	~2 (AF-2)	Inhibition of <i>umuCD</i> gene expression	ND	107

(Continued)

Table 1 (Continued)

SOS inhibitor	Bacterial species <sup>a</sup>	Times decrease in mutagenesis (inducer) <sup>b</sup>	Other phenotypes	Proposed mechanism of action	Ref.
Phytoncides	<i>S. Typhimurium</i>	ND	Inhibition of <i>umuCD</i> gene expression	ND	70
Cinnamon oil	<i>Escherichia coli</i>	ND	<ul style="list-style-type: none"> <li>■ Inhibition of Shiga toxin production</li> <li>■ Decrease in <i>oxyR</i>, <i>saxR</i>, and <i>rpoS</i> expression</li> </ul>	ND	143
<b>Ascorbic acid derivative</b>					
Disodium isostearyl 2-O-L-ascorbyl phosphate	<i>S. Typhimurium</i>	5 (MMNG)	Inhibition of <i>umuCD</i> gene expression	ND	69
<b>Organic compounds</b>					
Phthalocyanine tetrasulfonates	<i>Escherichia coli</i>	>8 (CIP)	<ul style="list-style-type: none"> <li>■ Inhibition of RecA ATPase, DNA-binding, DNA-strand-exchange, and LexA-proteolysis activities</li> <li>■ Potentiation of bactericidal antibiotic killing</li> <li>■ Inhibition of filamentation and biofilm formation</li> <li>■ Inhibition of generation of CIP-resistant mutants in a murine model</li> </ul>	Direct interaction with RecA protein	3
AHU3 (maleimide)	<i>Escherichia coli</i>	ND	<ul style="list-style-type: none"> <li>■ Inhibition of ATPase activity of RecA</li> <li>■ Reduction in RecA oligomerization</li> <li>■ Reduction of MMC-induced phage production</li> </ul> Inhibition of <i>Shiga</i> toxin production	Covalently binding to one or more of the three cysteine residues present in RecA	74

Abbreviations: AF-2, furilluramide; CIP, ciprofloxacin; ENU, N-ethyl-N-nitrosourea; MMC, mitomycin C; MMNG, methylnitrosoguanidin; ND, not determined; TET, tetracycline; UV, ultraviolet light.

<sup>a</sup>In vitro refers to experiments performed without bacterial cells (e.g., purified proteins in test tubes).

<sup>b</sup>Compared to the induced control. Data were interpolated from graphs when the actual values were not specified in the text; most values are therefore approximate.

Other potential inhibitors of SOS induction include several especially appealing antimicrobial molecules that have already been approved for human therapy. Novobiocin, an aminocoumarin antibiotic, blocks DNA gyrase and alters DNA supercoiling, which leads in turn to downregulation of *recA* expression in *S. aureus* (140). This downregulation reduces SOS induction and antibiotic-induced mutagenesis in *S. aureus* and *Acinetobacter baumannii* (80, 141). Another example is the antiprotozoal drug suramin, which reduces the SOS response in *M. tuberculosis*, potentiating ciprofloxacin activity (114). The aminoglycoside amikacin was similarly shown to reduce the ciprofloxacin-induced SOS response and mutagenesis in *P. aeruginosa* (152); in other bacterial species, however, aminoglycoside antibiotics were shown to induce the SOS response (10, 11). Antibiotics able to inhibit the SOS response therefore offer a unique opportunity for combined therapies designed both to kill bacteria and to inhibit the evolution of resistance.

Another interesting group of SOS inhibitors stems from plant compounds. Flavonoids such as genistein, daidzein, and baicalein (see **Table 1**) are natural inhibitors of mutagenesis mediated by the SOS response (107, 108, 123, 161). Baicalein can also inhibit antibiotic-induced ROS formation and ATP generation in *S. aureus* (123). Although the common mechanism underlying SOS inhibition by flavonoids is currently unknown, it is tempting to speculate that the antioxidant properties of flavonoids could reduce antibiotic-induced ROS, leading to a reduction in DNA damage (127). The antioxidant properties of other compounds also reduce mutagenesis caused by antibiotics without affecting their bactericidal activity (8).

A number of groups performed high-throughput screenings of chemical compound collections to find molecules able to block SOS induction by targeting specific RecA enzymatic activities. The search for molecules that inhibit RecA ATPase activity has yielded numerous potentially interesting compounds (20, 114, 125, 156, 157), although these SOS inhibitors have only begun to be tested in animal models. Alam and coworkers (3) found that phthalo-cyanine tetrasulfonates (PcT) block the ATPase, DNA-binding, DNA-strand-exchange, and LexA-proteolysis activities of RecA, inhibiting the SOS response. PcT compounds potentiate the bactericidal activity of several antibiotics while reducing the number of mutants after ciprofloxacin treatment, both in vitro and in a murine thigh infection model (3). To the best of our knowledge, this study was the first in which the activity of a SOS inhibitor was demonstrated in vivo, highlighting the potential benefits of SOS inhibition as a therapeutic target and paving the way for future studies.

Despite the therapeutic potential of RecA inhibitors, we should point out that RecA homologs have been found in eukaryotic cells, including human Rad51. RecA inhibitors for therapeutic purposes should thus be designed carefully to selectively target the prokaryotic protein. Conversely, LexA is a potentially safe target, as no eukaryotic homologs have been found. Mo and colleagues (110) developed an academic-industrial partnership to screen 1.8 million compounds for LexA self-cleavage inhibition activity that led to five promising new leads. Inhibition of LexA self-cleavage nevertheless does not increase bacterial susceptibility to antibiotics as much as does inhibition of RecA activity (110), probably due to the high basal RecA and TLS polymerase levels in the noninduced state.

## Horizontal Gene Transfer Inhibitors

Inhibiting the mechanisms that underlie the transfer of antibiotic resistance among bacterial pathogens is a strategy that might be used to combat the spread of resistance in some settings. Most work in this area was recently described in various excellent reviews, and we thus highlight only the more innovative and thought-provoking studies.

Inhibition of conjugation is one of the most appealing targets, since many antibiotic resistance genes are associated with large conjugative plasmids. Several molecules have been identified that



show promising conjugation inhibitory activities; unsaturated fatty acids are one of the most efficient. For more information regarding these molecules as well as their mechanism of action, we refer readers to a recent review, Reference 26.

Other studies have focused on directly eliminating plasmids, instead of inhibiting their transfer (4). Plasmid-curing compounds such as acridine orange or ethidium bromide have been known for decades, although most are mutagenic, which would preclude their use in clinical settings. A few recent reports highlight new strategies for plasmid curing. Ojala et al. (118) took advantage of the affinity of the lytic bacteriophage PRD1 for the conjugative pili encoded in a RP4 plasmid and found that the plasmid renders bacteria sensitive to phage killing. By coculturing plasmid-bearing bacteria with the phage, they showed that the plasmid was rapidly eliminated from bacterial populations, even in the presence of antibiotics against which the plasmid provided resistance. Kamruzzaman et al. (83) engineered interference plasmids by specifically deleting toxin genes from toxin-antitoxin systems and antibiotic-resistance genes from clinically relevant plasmids. These attenuated plasmids were able to displace their natural cognates in bacterial populations, both in culture media and in a mouse gut model, revealing a plausible strategy to eliminate prevalent plasmids from bacterial populations (83). For more data on plasmid-curing strategies, we refer readers to a recent review, Reference 91.

## CONCLUDING REMARKS

We must understand that bacterial resistance is the unavoidable consequence of the adaptive process of life. To date, no antimicrobial agent has escaped bacterial resistance. Looking at our recent history, resistance is thus probably impossible to eliminate, but we can try to hinder its progress in a cooperative endeavor by different disciplines, including medicine, genetics, microbiology, epidemiology, and sociology, always in the perspective of evolution. There are no simple solutions to this complex problem. Combined interventions are needed against emergence of antibiotic resistance, invasion, and occupation of a niche by resistant clones (14).

This article reviews how antibiotics affect emergence of resistance and the strategies that have been developed to avoid or reduce it, as well as its transmission by horizontal transfer. Most mechanisms reviewed here that promote the evolution of antimicrobial resistance stem from complex metabolic and genetic side effects of antibiotics; they are therefore to some extent the inevitable result of antibiotic use. They can probably be diminished or kept in check using tactics developed to combat the evolution of antibiotic resistance. Although some of these strategies show great potential, there is still a long way to go to effectively limit the generation and spread of antibiotic-resistance genes. More research, especially in *in vivo* models, is needed to ascertain the safety and efficacy of these compounds. Clinical trials might corroborate their effectiveness and stimulate wider use of these compounds in clinical settings. Such innovative therapies might nonetheless require changes in existing regulations, especially those concerning bacteriophages and genetically modified microorganisms.

It is time to adopt novel therapeutic approaches that target the generation and spread of antimicrobial resistance. It is our view that, in the near future, the combination of antibiotics with evolution-targeting drugs will be essential for offsetting the uncanny ability of bacteria to develop antibiotic resistance.

## DISCLOSURE STATEMENT

The authors are not aware of any affiliations, memberships, funding, or financial holdings that might be perceived as affecting the objectivity of this review.

## ACKNOWLEDGMENTS

We thank C. Mark for her exceptional editorial assistance. J.B. was supported by the Spanish Plan Nacional de I+D+i 2013–2016 and the Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases; grant REIPI RD16/0016/0009, cofinanced by the European Development Regional Fund “A Way to Achieve Europe” and by Operative Program Intelligent Growth 2014–2020; and grants FIS PI17/00159 (ISCIII/FEDER, UE) and SAF2015-72793-EXP (AEI/FEDER, UE). I.M. was supported by grants from the Agence Nationale de la Recherche grant IDEX ANR-11-IDEX-0005-01/ANR-11-LABX-0071, and the Fondation pour la Recherche Médicale grant DBF20160635736. J.R.-B. is a recipient of a Juan de la Cierva Fellowship, Ministerio de Economía Industria y Competitividad (FJCI-2016-30019).

## LITERATURE CITED

1. Aarestrup FM. 2005. Veterinary drug usage and antimicrobial resistance in bacteria of animal origin. *Basic Clin. Pharmacol. Toxicol.* 96:271–81
2. Al Mamun AA, Gautam S, Humayun MZ. 2006. Hypermutagenesis in mutA cells is mediated by mis-translational corruption of polymerase, and is accompanied by replication fork collapse. *Mol. Microbiol.* 62:1752–63
3. Alam MK, Alhazmi A, DeCoteau JF, Luo Y, Geyer CR. 2016. RecA inhibitors potentiate antibiotic activity and block evolution of antibiotic resistance. *Cell Chem. Biol.* 23:381–91
4. Amabile-Cuevas CF, Heinemann JA. 2004. Shooting the messenger of antibiotic resistance: plasmid elimination as a potential counter-evolutionary tactic. *Drug Discov. Today* 9:465–67
5. Andersson DI, Hughes D. 2014. Microbiological effects of sublethal levels of antibiotics. *Nat. Rev. Microbiol.* 12:465–78
6. Appelbaum PC. 2012. 2012 and beyond: potential for the start of a second pre-antibiotic era? *J. Antimicrob. Chemother.* 67:2062–68
7. Aranda J, Lopez M, Leiva E, Magan A, Adler B, et al. 2014. Role of *Acinetobacter baumannii* UmuD homologs in antibiotic resistance acquired through DNA damage-induced mutagenesis. *Antimicrob. Agents Chemother.* 58:1771–73
8. Arriaga-Alba M, Rivera-Sanchez R, Parra-Cervantes G, Barro-Moreno F, Flores-Paz R, Garcia-Jimenez E. 2000. Antimutagenesis of  $\beta$ -carotene to mutations induced by quinolone on *Salmonella typhimurium*. *Arch. Med. Res.* 31:156–61
9. Baharoglu Z, Babosan A, Mazel D. 2014. Identification of genes involved in low aminoglycoside-induced SOS response in *Vibrio cholerae*: a role for transcription stalling and Mfd helicase. *Nucleic Acids Res.* 42:2366–79
10. Baharoglu Z, Krin E, Mazel D. 2013. RpoS plays a central role in the SOS induction by sub-lethal aminoglycoside concentrations in *Vibrio cholerae*. *PLOS Genet.* 9(4):e1003421. <https://doi.org/10.1371/journal.pgen.1003421>
11. Baharoglu Z, Mazel D. 2011. *Vibrio cholerae* triggers SOS and mutagenesis in response to a wide range of antibiotics: a route towards multiresistance. *Antimicrob. Agents Chemother.* 55:2438–41
12. Baquero F. 2001. Low-level antibacterial resistance: a gateway to clinical resistance. *Drug Resist. Updates* 4:93–105
13. Baquero F, Coque TM, de la Cruz F. 2011. Ecology and evolution as targets: the need for novel eco-evo drugs and strategies to fight antibiotic resistance. *Antimicrob. Agents Chemother.* 55:3649–60
14. Baquero F, Lanza VF, Canton R, Coque TM. 2015. Public health evolutionary biology of antimicrobial resistance: priorities for intervention. *Evol. Appl.* 8:223–39
15. Baquero F, Negri MC. 1997. Selective compartments for resistant microorganisms in antibiotic gradients. *BioEssays* 19:731–36
16. Barbe J, Villaverde A, Guerrero R. 1983. Evolution of cellular ATP concentration after UV-mediated induction of SOS system in *Escherichia coli*. *Biochem. Biophys. Res. Commun.* 117:556–61

17. Battesti A, Majdalani N, Gottesman S. 2011. The RpoS-mediated general stress response in *Escherichia coli*. *Annu. Rev. Microbiol.* 65:189–213
18. Belenky P, Ye JD, Porter CB, Cohen NR, Lobritz MA, et al. 2015. Bactericidal antibiotics induce toxic metabolic perturbations that lead to cellular damage. *Cell Rep.* 13:968–80
19. Bellio P, Brisdelli F, Perilli M, Sabatini A, Bottoni C, et al. 2014. Curcumin inhibits the SOS response induced by levofloxacin in *Escherichia coli*. *Phytomedicine* 21:430–34
20. Bellio P, Di Pietro L, Mancini A, Piovano M, Nicoletti M, et al. 2017. SOS response in bacteria: inhibitory activity of lichen secondary metabolites against *Escherichia coli* RecA protein. *Phytomedicine* 29:11–18
21. Bernier SP, Lebeaux D, DeFrancesco AS, Valomon A, Soubigou G, et al. 2013. Starvation, together with the SOS response, mediates high biofilm-specific tolerance to the fluoroquinolone ofloxacin. *PLoS Genet.* 9:e1003144
22. Blázquez J. 2003. Hypermutation as a factor contributing to the acquisition of antimicrobial resistance. *Clin. Infect. Dis.* 37:1201–9
23. Boshoff HI, Reed MB, Barry CE 3rd, Mizrahi V. 2003. DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in *Mycobacterium tuberculosis*. *Cell* 113:183–93
24. Bunnell BE, Escobar JF, Bair KL, Sutton MD, Crane JK. 2017. Zinc blocks SOS-induced antibiotic resistance via inhibition of RecA in *Escherichia coli*. *PLoS ONE* 12:e0178303
25. Cabello FC. 2006. Heavy use of prophylactic antibiotics in aquaculture: a growing problem for human and animal health and for the environment. *Environ. Microbiol.* 8:1137–44
26. Cabezon E, de la Cruz F, Arechaga I. 2017. Conjugation inhibitors and their potential use to prevent dissemination of antibiotic resistance genes in bacteria. *Front. Microbiol.* 8:2329
27. Castaneda-García A, Prieto AI, Rodríguez-Beltrán J, Alonso N, Cantillon D, et al. 2017. A non-canonical mismatch repair pathway in prokaryotes. *Nat. Commun.* 8:14246
28. Chiang SM, Schellhorn HE. 2010. Evolution of the RpoS regulon: origin of RpoS and the conservation of RpoS-dependent regulation in bacteria. *J. Mol. Evol.* 70:557–71
29. Ciofu O, Mandsberg LF, Bjarnsholt T, Wassermann T, Hoiby N. 2010. Genetic adaptation of *Pseudomonas aeruginosa* during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants. *Microbiology* 156:1108–19
30. Cirz RT, Chin JK, Andes DR, de Crecy-Lagard V, Craig WA, Romesberg FE. 2005. Inhibition of mutation and combating the evolution of antibiotic resistance. *PLoS Biol.* 3:e176
31. Cirz RT, Romesberg FE. 2007. Controlling mutation: intervening in evolution as a therapeutic strategy. *Crit. Rev. Biochem. Mol. Biol.* 42:341–54
32. Cline DJ, Holt SL, Singleton SF. 2007. Inhibition of *Escherichia coli* RecA by rationally redesigned N-terminal helix. *Org. Biomol. Chem.* 5:1525–28
33. Couce A, Blázquez J. 2009. Side effects of antibiotics on genetic variability. *FEMS Microbiol. Rev.* 33:531–38
34. Cox EC, Gibson TC. 1974. Selection for high mutation rates in chemostats. *Genetics* 77:169–84
35. Cox MM. 2007. Regulation of bacterial RecA protein function. *Crit. Rev. Biochem. Mol. Biol.* 42:41–63
36. Crane JK, Broome JE, Reddinger RM, Werth BB. 2014. Zinc protects against *Shiga*-toxicogenic *Escherichia coli* by acting on host tissues as well as on bacteria. *BMC Microbiol.* 14:145
37. Culyba MJ, Mo CY, Kohli RM. 2015. Targets for combating the evolution of acquired antibiotic resistance. *Biochemistry* 54:3573–82
38. Dahan-Grobeld E, Livneh Z, Maretzek AF, Polak-Charcon S, Eichenbaum Z, Degani H. 1998. Reversible induction of ATP synthesis by DNA damage and repair in *Escherichia coli*: in vivo NMR studies. *J. Biol. Chem.* 273:30232–38
39. Dapa T, Fleurier S, Bredeche MF, Matic I. 2017. The SOS and RpoS regulons contribute to bacterial cell robustness to genotoxic stress by synergistically regulating DNA polymerase pol II. *Genetics* 206:1349–60
40. Davies J. 1994. Inactivation of antibiotics and the dissemination of resistance genes. *Science* 264:375–82
41. Davies J, Spiegelman GB, Yim G. 2006. The world of subinhibitory antibiotic concentrations. *Curr. Opin. Microbiol.* 9:445–53
42. Denamur E, Matic I. 2006. Evolution of mutation rates in bacteria. *Mol. Microbiol.* 60:820–27
43. Denamur E, Tenailon O, Deschamps C, Skurnik D, Ronco E, et al. 2005. Intermediate mutation frequencies favor evolution of multidrug resistance in *Escherichia coli*. *Genetics* 171:825–27

44. Didelot X, Maiden MC. 2010. Impact of recombination on bacterial evolution. *Trends Microbiol.* 18:315–22
45. Didier JP, Villet R, Huggler E, Lew DP, Hooper DC, et al. 2011. Impact of ciprofloxacin exposure on *Staphylococcus aureus* genomic alterations linked with emergence of rifampin resistance. *Antimicrob. Agents Chemother.* 55:1946–52
46. Dorr T, Lewis K, Vulic M. 2009. SOS response induces persistence to fluoroquinolones in *Escherichia coli*. *PLoS Genet.* 5:e1000760
47. Dwyer DJ, Belenky PA, Yang JH, MacDonald IC, Martell JD, et al. 2014. Antibiotics induce redox-related physiological alterations as part of their lethality. *PNAS* 111:E2100–9
48. Erill I, Campoy S, Barbe J. 2007. Aeons of distress: an evolutionary perspective on the bacterial SOS response. *FEMS Microbiol. Rev.* 31:637–56
49. Fornelos N, Browning DF, Butala M. 2016. The use and abuse of LexA by mobile genetic elements. *Trends Microbiol.* 24:391–401
50. Foster PL. 2007. Stress-induced mutagenesis in bacteria. *Crit. Rev. Biochem. Mol. Biol.* 42:373–97
51. Foti JJ, Devados B, Winkler JA, Collins JJ, Walker GC. 2012. Oxidation of the guanine nucleotide pool underlies cell death by bactericidal antibiotics. *Science* 336:315–19
52. Frenoy A, Bonhoeffer S. 2018. Death and population dynamics affect mutation rate estimates and evolvability under stress in bacteria. *PLOS Biol.* 16(5):e2005056
53. Frisch RL, Su Y, Thornton PC, Gibson JL, Rosenberg SM, Hastings PJ. 2010. Separate DNA Pol II- and Pol IV-dependent pathways of stress-induced mutation during double-strand-break repair in *Escherichia coli* are controlled by RpoS. *J. Bacteriol.* 192:4694–700
54. Fung-Tomc J, Kolek B, Bonner DP. 1993. Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in *Pseudomonas aeruginosa* and methicillin-resistant *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* 37:1289–96
55. Gibson TC, Scheppe ML, Cox EC. 1970. Fitness of an *Escherichia coli* mutator gene. *Science* 169:686–88
56. Gillespie SH, Basu S, Dickens AL, O’Sullivan DM, McHugh TD. 2005. Effect of subinhibitory concentrations of ciprofloxacin on *Mycobacterium fortuitum* mutation rates. *J. Antimicrob. Chemother.* 56:344–48
57. Giroux X, Su W, Bredeche M, Matic I. 2017. Maladaptive DNA repair activity is the ultimate contributor to the death of trimethoprim-treated cells under aerobic and anaerobic conditions. *PNAS* 114:11512–17
58. Goerke C, Koller J, Wolz C. 2006. Ciprofloxacin and trimethoprim cause phage induction and virulence modulation in *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* 50:171–77
59. Goh EB, Yim G, Tsui W, McClure J, Surette MG, Davies J. 2002. Transcriptional modulation of bacterial gene expression by subinhibitory concentrations of antibiotics. *PNAS* 99:17025–30
60. Goneau LW, Hannan TJ, MacPhee RA, Schwartz DJ, Macklaim JM, et al. 2015. Subinhibitory antibiotic therapy alters recurrent urinary tract infection pathogenesis through modulation of bacterial virulence and host immunity. *mBio* 6:e00356-15
61. Goodman MF. 2014. The discovery of error-prone DNA polymerase V and its unique regulation by RecA and ATP. *J. Biol. Chem.* 289:26772–82
62. Goswami M, Mangoli SH, Jawali N. 2006. Involvement of reactive oxygen species in the action of ciprofloxacin against *Escherichia coli*. *Antimicrob. Agents Chemother.* 50:949–54
63. Goulas A, Haudin CS, Bergheaud V, Dumeny V, Ferhi S, et al. 2016. A new extraction method to assess the environmental availability of ciprofloxacin in agricultural soils amended with exogenous organic matter. *Chemosphere* 165:460–69
64. Guerin E, Cambray G, Sanchez-Alberola N, Campoy S, Erill I, et al. 2009. The SOS response controls integron recombination. *Science* 324:1034
65. Gullberg E, Cao S, Berg OG, Ilback C, Sandegren L, et al. 2011. Selection of resistant bacteria at very low antibiotic concentrations. *PLOS Pathog.* 7:e1002158
66. Gutierrez A, Laureti L, Crussard S, Abida H, Rodríguez-Rojas A, et al. 2013.  $\beta$ -Lactam antibiotics promote bacterial mutagenesis via an RpoS-mediated reduction in replication fidelity. *Nat. Commun.* 4:1610
67. Hastings PJ, Rosenberg SM, Slack A. 2004. Antibiotic-induced lateral transfer of antibiotic resistance. *Trends Microbiol.* 12:401–4

68. Henderson-Begg SK, Livermore DM, Hall LM. 2006. Effect of subinhibitory concentrations of antibiotics on mutation frequency in *Streptococcus pneumoniae*. *J. Antimicrob. Chemother.* 57:849–54
69. Hisama M, Matsuda S, Shibayama H, Iwaki M. 2008. Antimutagenic activity of a novel ascorbic derivative, disodium isostearyl 2-*O*-L-ascorbyl phosphate. *Yakugaku Zasshi* 128:933–40
70. Hisama M, Matsuda S, Tanaka T, Shibayama H, Nomura M, Iwaki M. 2008. Suppression of mutagens-induced SOS response by phytoncide solution using *Salmonella typhimurium* TA1535/pSK1002 *umu* test. *J. Oleo Sci.* 57:381–90
71. Hocquet D, Bertrand X. 2014. Metronidazole increases the emergence of ciprofloxacin- and amikacin-resistant *Pseudomonas aeruginosa* by inducing the SOS response. *J. Antimicrob. Chemother.* 69:852–54
72. Hocquet D, Llanes C, Thouverez M, Kulasekara HD, Bertrand X, et al. 2012. Evidence for induction of integron-based antibiotic resistance by the SOS response in a clinical setting. *PLOS Pathog.* 8:e1002778
73. Holmes AH, Moore LS, Sundsfjord A, Steinbakk M, Regmi S, et al. 2016. Understanding the mechanisms and drivers of antimicrobial resistance. *Lancet* 387:176–87
74. Huerta-Uribe A, Marjenberg ZR, Yamaguchi N, Fitzgerald S, Connolly JP, et al. 2016. Identification and characterization of novel compounds blocking *Shiga* toxin expression in *Escherichia coli* O157:H7. *Front. Microbiol.* 7:1930
75. Hughes D, Andersson DI. 2012. Selection of resistance at lethal and non-lethal antibiotic concentrations. *Curr. Opin. Microbiol.* 15:555–60
76. Hughes D, Andersson DI. 2017. Evolutionary trajectories to antibiotic resistance. *Annu. Rev. Microbiol.* 71:579–96
77. Imamovic L, Sommer MO. 2013. Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. *Sci. Transl. Med.* 5:204ra132
78. Imlay JA. 2009. Oxidative stress. *EcoSal Plus* 2009. <https://doi.org/10.1128/ecosalplus.5.4.4>
79. Ippoliti PJ, Delateur NA, Jones KM, Beuning PJ. 2012. Multiple strategies for translesion synthesis in bacteria. *Cells* 1:799–831
80. Jara LM, Perez-Varela M, Corral J, Arch M, Cortes P, et al. 2015. Novobiocin inhibits the antimicrobial resistance acquired through DNA damage-induced mutagenesis in *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* 60:637–39
81. Jee J, Rasouly A, Shamovsky I, Akeviz Y, Steinman SR, et al. 2016. Rates and mechanisms of bacterial mutagenesis from maximum-depth sequencing. *Nature* 534:693–96
82. Jones-Lepp TL. 2006. Chemical markers of human waste contamination: analysis of urobilin and pharmaceuticals in source waters. *J. Environ. Monit.* 8:472–78
83. Kamruzzaman M, Shoma S, Thomas CM, Partridge SR, Iredell JR. 2017. Plasmid interference for curing antibiotic resistance plasmids in vivo. *PLOS ONE* 12:e0172913
84. Kasprzyk-Hordern B, Dinsdale RM, Guwy AJ. 2008. The occurrence of pharmaceuticals, personal care products, endocrine disruptors and illicit drugs in surface water in South Wales, UK. *Water Res.* 42:3498–518
85. Kim S, Lieberman TD, Kishony R. 2014. Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance. *PNAS* 111:14494–99
86. Kohanski MA, DePristo MA, Collins JJ. 2010. Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis. *Mol. Cell* 37:311–20
87. Konola JT, Sargent KE, Gow JB. 2000. Efficient repair of hydrogen peroxide-induced DNA damage by *Escherichia coli* requires SOS induction of RecA and RuvA proteins. *Mutat. Res.* 459:187–94
88. Laureti L, Matic I, Gutierrez A. 2013. Bacterial responses and genome instability induced by subinhibitory concentrations of antibiotics. *Antibiotics* 2:100–14
89. Lee AM, Ross CT, Zeng BB, Singleton SF. 2005. A molecular target for suppression of the evolution of antibiotic resistance: inhibition of the *Escherichia coli* RecA protein by  $N^6$ -(1-naphthyl)-ADP. *J. Med. Chem.* 48:5408–11
90. Lee AM, Singleton SF. 2004. Inhibition of the *Escherichia coli* RecA protein: zinc(II), copper(II) and mercury(II) trap RecA as inactive aggregates. *J. Inorg. Biochem.* 98:1981–86
91. Letchumanan V, Chan KG, Lee LH. 2015. An insight of traditional plasmid curing in *Vibrio* species. *Front. Microbiol.* 6:735



92. Levin DE, Marnett LJ, Ames BN. 1984. Spontaneous and mutagen-induced deletions: mechanistic studies in *Salmonella* tester strain TA102. *PNAS* 81:4457–61
93. Lewin CS, Amyes SG. 1991. The role of the SOS response in bacteria exposed to zidovudine or trimethoprim. *J. Med. Microbiol.* 34:329–32
94. Liu P, Wu Z, Xue H, Zhao X. 2017. Antibiotics trigger initiation of SCCmec transfer by inducing SOS responses. *Nucleic Acids Res.* 45:3944–52
95. Lobritz MA, Belenky P, Porter CB, Gutierrez A, Yang JH, et al. 2015. Antibiotic efficacy is linked to bacterial cellular respiration. *PNAS* 112:8173–80
96. Long H, Miller SF, Strauss C, Zhao C, Cheng L, et al. 2016. Antibiotic treatment enhances the genome-wide mutation rate of target cells. *PNAS* 113:E2498–505
97. López E, Elez M, Matic I, Blázquez J. 2007. Antibiotic-mediated recombination: ciprofloxacin stimulates SOS-independent recombination of divergent sequences in *Escherichia coli*. *Mol. Microbiol.* 64:83–93
98. Lorian V. 1975. Some effects of subinhibitory concentrations of antibiotics on bacteria. *Bull. N. Y. Acad. Med.* 51:1046–55
99. Lu TK, Collins JJ. 2009. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. *PNAS* 106:4629–34
100. Maciá MD, Blanquer D, Togores B, Sauleda J, Pérez JL, Oliver A. 2005. Hypermutation is a key factor in development of multiple-antimicrobial resistance in *Pseudomonas aeruginosa* strains causing chronic lung infections. *Antimicrob. Agents Chemother.* 49:3382–86
101. Maiques E, Ubeda C, Campoy S, Salvador N, Lasa I, et al. 2006.  $\beta$ -Lactam antibiotics induce the SOS response and horizontal transfer of virulence factors in *Staphylococcus aureus*. *J. Bacteriol.* 188:2726–29
102. Mao EF, Lane L, Lee J, Miller JH. 1997. Proliferation of mutators in A cell population. *J. Bacteriol.* 179:417–22
103. Mathieu A, Fleurier S, Frenoy A, Dairou J, Bredeche MF, et al. 2016. Discovery and function of a general core hormetic stress response in *E. coli* induced by sublethal concentrations of antibiotics. *Cell Rep.* 17:46–57
104. McManus PS, Stockwell VO, Sundin GW, Jones AL. 2002. Antibiotic use in plant agriculture. *Annu. Rev. Phytopathol.* 40:443–65
105. Miller C, Thomsen LE, Gaggero C, Mosseri R, Ingmer H, Cohen SN. 2004. SOS response induction by  $\beta$ -lactams and bacterial defense against antibiotic lethality. *Science* 305:1629–31
106. Miller JH. 1998. Mutators in *Escherichia coli*. *Mutat. Res.* 409:99–106
107. Miyazawa M, Hisama M. 2003. Antimutagenic activity of flavonoids from *Chrysanthemum morifolium*. *Biosci. Biotechnol. Biochem.* 67:2091–99
108. Miyazawa M, Sakano K, Nakamura S, Kosaka H. 1999. Antimutagenic activity of isoflavones from soybean seeds (*Glycine max* Merrill). *J. Agric. Food Chem.* 47:1346–49
109. Miyazawa M, Sakano K, Nakamura S, Kosaka H. 2001. Antimutagenic activity of isoflavone from *Pueraria lobata*. *J. Agric. Food Chem.* 49:336–41
110. Mo CY, Culyba MJ, Selwood T, Kubiak JM, Hostetler ZM, et al. 2018. Inhibitors of LexA autoproteolysis and the bacterial SOS response discovered by an academic-industry partnership. *ACS Infect. Dis.* 4:349–59
111. Mo CY, Manning SA, Roggiani M, Culyba MJ, Samuels AN, et al. 2016. Systematically altering bacterial SOS activity under stress reveals therapeutic strategies for potentiating antibiotics. *mSphere* 1:e00163–16
112. Nagel M, Reuter T, Jansen A, Szekat C, Bierbaum G. 2011. Influence of ciprofloxacin and vancomycin on mutation rate and transposition of IS256 in *Staphylococcus aureus*. *Int. J. Med. Microbiol.* 301:229–36
113. Nair CG, Chao C, Ryall B, Williams HD. 2012. Sub-lethal concentrations of antibiotics increase mutation frequency in the cystic fibrosis pathogen *Pseudomonas aeruginosa*. *Lett. Appl. Microbiol.* 56:149–54
114. Nautiyal A, Patil KN, Muniyappa K. 2014. Suramin is a potent and selective inhibitor of *Mycobacterium tuberculosis* RecA protein and the SOS response: RecA as a potential target for antibacterial drug discovery. *J. Antimicrob. Chemother.* 69:1834–43
115. Newcombe HB. 1949. Origin of bacterial variants. *Nature* 164:150
116. Nohmi T. 2006. Environmental stress and lesion-bypass DNA polymerases. *Annu. Rev. Microbiol.* 60:231–53



117. Oethinger M, Kern WV, Jellen-Ritter AS, McMurry LM, Levy SB. 2000. Ineffectiveness of topoiso-erase mutations in mediating clinically significant fluoroquinolone resistance in *Escherichia coli* in the absence of the AcrAB efflux pump. *Antimicrob. Agents Chemother.* 44:10–13
118. Ojala V, Laitalainen J, Jalasvuori M. 2013. Fight evolution with evolution: plasmid-dependent phages with a wide host range prevent the spread of antibiotic resistance. *Evol. Appl.* 6:925–32
119. Oliver A, Baquero F, Blázquez J. 2002. The mismatch repair system (mutS, mutL and uvrD genes) in *Pseudomonas aeruginosa*: molecular characterization of naturally occurring mutants. *Mol. Microbiol.* 43:1641–50
120. Oliver A, Cantón R, Campo P, Baquero F, Blázquez J. 2000. High frequency of hypermutable *Pseudomonas aeruginosa* in cystic fibrosis lung infection. *Science* 288:1251–54
121. Orlen H, Hughes D. 2006. Weak mutators can drive the evolution of fluoroquinolone resistance in *Escherichia coli*. *Antimicrob. Agents Chemother.* 50:3454–56
122. Pal C, Papp B, Lazar V. 2015. Collateral sensitivity of antibiotic-resistant microbes. *Trends Microbiol.* 23:401–7
123. Peng Q, Zhou S, Yao F, Hou B, Huang Y, et al. 2011. Baicalein suppresses the SOS response system of *Staphylococcus aureus* induced by ciprofloxacin. *Cell Physiol. Biochem.* 28:1045–50
124. Pérez-Capilla T, Baquero MR, Gómez-Gómez JM, Ionel A, Martín S, Blázquez J. 2005. SOS-independent induction of dinB transcription by  $\beta$ -lactam-mediated inhibition of cell wall synthesis in *Escherichia coli*. *J. Bacteriol.* 187:1515–18
125. Peterson EJ, Janzen WP, Kireev D, Singleton SF. 2012. High-throughput screening for RecA inhibitors using a transcriber adenosine 5'-O-diphosphate assay. *Assay Drug Dev. Technol.* 10:260–68
126. Phillips I, Culebras E, Moreno F, Baquero F. 1987. Induction of the SOS response by new 4-quinolones. *J. Antimicrob. Chemother.* 20:631–38
127. Pietta PG. 2000. Flavonoids as antioxidants. *J. Nat. Prod.* 63:1035–42
128. Pletz MW, Rau M, Bulitta J, De Roux A, Burkhardt O, et al. 2004. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. *Antimicrob. Agents Chemother.* 48:3765–72
129. Pomerantz RT, Goodman MF, O'Donnell ME. 2013. DNA polymerases are error-prone at RecA-mediated recombination intermediates. *Cell Cycle* 12:2558–63
130. Quoc Tuc D, Elodie MG, Pierre L, Fabrice A, Marie-Jeanne T, et al. 2017. Fate of antibiotics from hospital and domestic sources in a sewage network. *Sci. Total Environ.* 575:758–66
131. Radman M, Taddei F, Matic I. 2000. Evolution-driving genes. *Res. Microbiol.* 151:91–95
132. Rayssiguier C, Thaler DS, Radman M. 1989. The barrier to recombination between *Escherichia coli* and *Salmonella typhimurium* is disrupted in mismatch-repair mutants. *Nature* 342:396–401
133. Recacha E, Machuca J, Diaz de Alba P, Ramos-Guelfo M, Docobo-Perez F, et al. 2017. Quinolone resistance reversion by targeting the SOS response. *mBio* 8:e00971-17
134. Ren L, Rahman MS, Humayun MZ. 1999. *Escherichia coli* cells exposed to streptomycin display a mutator phenotype. *J. Bacteriol.* 181:1043–44
135. Rodríguez-Beltrán J, Tourret J, Tenaillon O, López E, Bourdelier E, et al. 2015. High recombinant frequency in extraintestinal pathogenic *Escherichia coli* strains. *Mol. Biol. Evol.* 32:1708–16
136. Rodríguez-Rojas A, Couce A, Blázquez J. 2010. Frequency of spontaneous resistance to fosfomicin combined with different antibiotics in *Pseudomonas aeruginosa*. *Antimicrob. Agents Chemother.* 54:4948–49
137. Rodríguez-Rojas A, Makarova O, Rolff J. 2014. Antimicrobials, stress and mutagenesis. *PLOS Pathog.* 10:e1004445
138. Rosenberg SM. 2001. Evolving responsively: adaptive mutation. *Nat. Rev. Genet.* 2:504–15
139. Sangurdekar DP, Zhang Z, Khodursky AB. 2011. The association of DNA damage response and nucleotide level modulation with the antibacterial mechanism of the anti-folate drug trimethoprim. *BMC Genom.* 12:583
140. Schroder W, Bernhardt J, Marincola G, Klein-Hitpass L, Herbig A, et al. 2014. Altering gene expression by aminocoumarins: the role of DNA supercoiling in *Staphylococcus aureus*. *BMC Genom.* 15:291
141. Schroder W, Goerke C, Wolz C. 2013. Opposing effects of aminocoumarins and fluoroquinolones on the SOS response and adaptability in *Staphylococcus aureus*. *J. Antimicrob. Chemother.* 68:529–38

142. Shaver AC, Dombrowski PG, Sweeney JY, Treis T, Zappala RM, Sniegowski PD. 2002. Fitness evolution and the rise of mutator alleles in experimental *Escherichia coli* populations. *Genetics* 162:557–66
143. Sheng L, Rasco B, Zhu MJ. 2016. Cinnamon oil inhibits *Shiga* toxin type 2 phage induction and *Shiga* toxin type 2 production in *Escherichia coli* O157:H7. *Appl. Environ. Microbiol.* 82:6531–40
144. Simmons LA, Foti JJ, Cohen SE, Walker GC. 2008. The SOS regulatory network. *EcoSal Plus* 2008. <https://doi.org/10.1128/ecosalplus.5.4.3>
145. Sioud M, Boudabous A, Cekaite L. 2009. Transcriptional responses of *Bacillus subtilis* and *thuringiensis* to antibiotics and anti-tumour drugs. *Int. J. Mol. Med.* 23:33–39
146. Smith PA, Romesberg FE. 2007. Combating bacteria and drug resistance by inhibiting mechanisms of persistence and adaptation. *Nat. Chem. Biol.* 3:549–56
147. Song LY, Goff M, Davidian C, Mao Z, London M, et al. 2016. Mutational consequences of ciprofloxacin in *Escherichia coli*. *Antimicrob. Agents Chemother.* 60:6165–72
148. Tanimoto K, Tomita H, Fujimoto S, Okuzumi K, Ike Y. 2008. Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in *Pseudomonas aeruginosa*, but use of the high-potency drug doripenem inhibits mutant formation. *Antimicrob. Agents Chemother.* 52:3795–800
149. Thi TD, López E, Rodríguez-Rojas A, Rodríguez-Beltrán J, Couce A, et al. 2011. Effect of recA inactivation on mutagenesis of *Escherichia coli* exposed to sublethal concentrations of antimicrobials. *J. Antimicrob. Chemother.* 66:531–38
150. Torres-Barcelo C, Kojadinovic M, Moxon R, MacLean RC. 2015. The SOS response increases bacterial fitness, but not evolvability, under a sublethal dose of antibiotic. *Proc. Biol. Sci.* 282:20150885
151. Vaisman A, McDonald JP, Woodgate R. 2012. Translesion DNA synthesis. *EcoSal Plus* 2012. <https://doi.org/10.1128/ecosalplus.7.2.2>
152. Valencia EY, Esposito F, Spira B, Blázquez J, Galhardo RS. 2017. Ciprofloxacin-mediated mutagenesis is suppressed by subinhibitory concentrations of amikacin in *Pseudomonas aeruginosa*. *Antimicrob. Agents Chemother.* 61:e02107-16
153. Veigl ML, Schneider S, Mollis S, Sedwick WD. 1991. Specificities mediated by neighboring nucleotides appear to underlie mutation induced by antifolates in *E. coli*. *Mutat. Res.* 246:75–91
154. Waksman SA. 1947. What is an antibiotic or an antibiotic substance? *Mycologia* 39:565–69
155. Wigle TJ, Lee AM, Singleton SF. 2006. Conformationally selective binding of nucleotide analogues to *Escherichia coli* RecA: a ligand-based analysis of the RecA ATP binding site. *Biochemistry* 45:4502–13
156. Wigle TJ, Sexton JZ, Gromova AV, Hadimani MB, Hughes MA, et al. 2009. Inhibitors of RecA activity discovered by high-throughput screening: cell-permeable small molecules attenuate the SOS response in *Escherichia coli*. *J. Biomol. Screen.* 14:1092–101
157. Wigle TJ, Singleton SF. 2007. Directed molecular screening for RecA ATPase inhibitors. *Bioorg. Med. Chem. Lett.* 17:3249–53
158. Witte W. 1998. Medical consequences of antibiotic use in agriculture. *Science* 279:996–97
159. Yakimov A, Pobegalov G, Bakhlanova I, Khodorkovskii M, Petukhov M, Baitin D. 2017. Blocking the RecA activity and SOS-response in bacteria with a short alpha-helical peptide. *Nucleic Acids Res.* 45:9788–96
160. Yamada M, Nunoshiba T, Shimizu M, Gruz P, Kamiya H, et al. 2006. Involvement of Y-family DNA polymerases in mutagenesis caused by oxidized nucleotides in *Escherichia coli*. *J. Bacteriol.* 188:4992–95
161. Yang Y, Fix D. 2006. Genetic analysis of the anti-mutagenic effect of genistein in *Escherichia coli*. *Mutat. Res.* 600:193–206
162. Yim G, McClure J, Surette MG, Davies JE. 2011. Modulation of *Salmonella* gene expression by subinhibitory concentrations of quinolones. *J. Antibiot.* 64:73–78
163. Ysern P, Clerch B, Castano M, Gibert I, Barbe J, Llagostera M. 1990. Induction of SOS genes in *Escherichia coli* and mutagenesis in *Salmonella typhimurium* by fluoroquinolones. *Mutagenesis* 5:63–66

# Contents

The Outer Membrane Took Center Stage <i>Volkmar Braun</i> .....	1
Control of Specialized Metabolism by Signaling and Transcriptional Regulation: Opportunities for New Platforms for Drug Discovery? <i>M. Daniel-Ivad, S. Pimentel-Elardo, and J.R. Nodwell</i> .....	25
Above and Beyond Watson and Crick: Guanine Quadruplex Structures and Microbes <i>H Steven Seifert</i> .....	49
The Clash of Macromolecular Titans: Replication-Transcription Conflicts in Bacteria <i>Kevin S. Lang and Houra Merrikh</i> .....	71
Eco-evolutionary Dynamics Linked to Horizontal Gene Transfer in Vibrios <i>Frédérique Le Roux and Melanie Blokesch</i> .....	89
The Complex Rcs Regulatory Cascade <i>Erin Wall, Nadim Majdalani, and Susan Gottesman</i> .....	111
Broadening the Definition of Bacterial Small RNAs: Characteristics and Mechanisms of Action <i>Marie-Claude Carrier, David Lalaouna, and Eric Massé</i> .....	141
Transcriptional Responses to ppGpp and DksA <i>Richard L. Gourse, Albert Y. Chen, Saumya Gopalkrishnan, Patricia Sanchez-Vazquez, Angela Myers, and Wilma Ross</i> .....	163
Context-Specific Action of Ribosomal Antibiotics <i>Nora Vázquez-Laslop and Alexander S. Mankin</i> .....	185
Antibiotic-Induced Genetic Variation: How It Arises and How It Can Be Prevented <i>Jesús Blázquez, Jerónimo Rodríguez-Beltrán, and Ivan Matic</i> .....	209
Using Cryo-EM to Investigate Bacterial Secretion Systems <i>Chiara Rapisarda, Matteo Tassinari, Francesca Gubellini, and Rémi Fronzes</i> .....	231
A New Lens for RNA Localization: Liquid-Liquid Phase Separation <i>Erin M. Langdon and Amy S. Gladfelter</i> .....	255

The Promise of a Malaria Vaccine—Are We Closer? <i>Matthew B. Laurens</i> .....	273
Spo11-Independent Meiosis in Social Amoebae <i>Gareth Bloomfield</i> .....	293
The Glyoxylate Shunt, 60 Years On <i>Stephen K. Dolan and Martin Welch</i> .....	309
Electron Bifurcation: A Long-Hidden Energy-Coupling Mechanism <i>Volker Müller, Nilanjan Pal Chowdbury, and Mirko Basen</i> .....	331
Epigenetic Variation and Regulation in Malaria Parasites <i>Manoj T. Duraisingh and Kristen M. Skillman</i> .....	355
Interspecific Gene Exchange as a Driver of Adaptive Evolution in Fungi <i>Alice Feurtey and Eva H. Stukenbrock</i> .....	377
Communication Between the Microbiota and Mammalian Immunity <i>Kyla S. Ost and June L. Round</i> .....	399
Ebola: Lessons on Vaccine Development <i>Heinz Feldmann, Friederike Feldmann, and Andrea Marzi</i> .....	423
Detection of Microbial Infections Through Innate Immune Sensing of Nucleic Acids <i>Xiaojun Tan, Lijun Sun, Jueqi Chen, and Zhijian J. Chen</i> .....	447
The Epigenome, Cell Cycle, and Development in <i>Toxoplasma</i> <i>Kami Kim</i> .....	479
Regulation of Sexual Commitment and Gametocytogenesis in Malaria Parasites <i>Gabrielle A. Josling, Kim C. Williamson, and Manuel Llinás</i> .....	501
Pneumococcal Vaccines: Host Interactions, Population Dynamics, and Design Principles <i>Nicholas J. Croucher, Alessandra Løchen, and Stephen D. Bentley</i> .....	521

## Indexes

Cumulative Index of Contributing Authors, Volumes 68–72 .....	551
---	-----

## Errata

An online log of corrections to *Annual Review of Microbiology* articles may be found at  
<http://www.annualreviews.org/errata/micro>